Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Issue Date
1992-10-01
Metadata
Show full item recordCitation
Læknablaðið 1992, 78(8):323-9Abstract
Eleven patients with chronic inflammatory arthritides, Hb<105g/1 and symptoms from their anemia were treated with recombinant human erythropoietin for 6 weeks, of a dose of 250 IU/kg/week, administered as subcutaneous injections 5 days per week. All patients had active inflammatory disease. Nine patients responded to therapy with an increase in hemoglobin of more than 15 g/1. The mean hemoglobin increased from 93.0 ± 8.0 g/1 before treatment to 115.0 ± 12.0 g/1 after 6 weeks (p<0.001). There was no correlation between the initial serum erythropoietin level and the response. In conclusion, anemia in chronic inflammatory arthritides responds to treatment with subcutaneous injections of recombinant human erythropoietin.Ellefu sjúklingar með langvinna liðagigt og einkenni vegna blóðskorts (Hb<105 g/1) voru meðhöndlaðir í sex vikur með rauðkornavaka (recombinant human erythropoietin). Gefnar voru undir húð 50 alþjóðlegar einingar/kg fimm daga í viku. Allir sjúklingarnir höfðu virka liðagigt. Níu sjúklingar svöruðu meðferðinni með aukningu í blóðrauða með meira en 15 g/1. Meðal blóðgildið jókst frá 93,0 ± 8,0 g/1 til 115,0 ± 12,0 g/1 eftir sex vikna meðferð (p<0,001). Ekkert samband fannst milli rauðkornavaka í sermi og svörun við meðferð. Niðurstöður benda til að sjúklingar sem þjást af blóðskorti vegna langvinnrar liðagigtar svari meðferð með rauðkornavaka gefnum undir húð.
Description
Neðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn View/OpenAdditional Links
http://www.laeknabladid.isCollections